Popular on EntSun
- From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC) - 197
- Elaine Sanders Mayfield Announces Inspiring New Gospel Single "Once Again" - 161
- Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio - 158
- DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care - 155
- Petal & Pup and The Somewhere Co. Launch Limited-Edition Collection for U.S. Customers - 153
- Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 139
- Where Is Your Faith The Movie and Sountrack - 134
- Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will - 133
- UK Financial Ltd Verifies Maya Preferred PRA Circulating Supply, Proving Its Eight-Year Promise of Under 1M Tokens After Chainlink Labs Agreement - 132
- New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering - 124
Similar on EntSun
- KT Medical Staffing Addresses the Questions Families Forget to Ask Before Bringing Private Nursing Care Home
- Private Autopsies Give Arizona Families Answers After Nursing Home and Care Facility Deaths
- Contracting Resources Group Named to Inc. 5000 for the Ninth Time
- Lineus Medical Elevates Leadership to Accelerate Growth After Breakthrough Clinical Results
- Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
- Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
- FDA Food Recall Notices After Outbreak Linked to 98 Hospitalizations: Practical Tips for Safer Grocery Shopping
- Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
- DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
Mativa Diagnostics & UGenome AI Announce Strategic Partnership to Bring Precision to Maternal Health
EntSun News/11099498
BOSTON - EntSun -- Philadelphia, PA – Mativa Diagnostics, an ultrasensitive biomarker IP-driven company, today announced a strategic partnership with UGenome AI to integrate advanced genomic and transcriptomic analytics into Mativa's rapidly expanding maternal health ecosystem. This collaboration aligns UGenome's vision of accessible genomic medicine with Mativa's focus on its MSight Diagnostic Device and MatBank biorepository.
A core pillar of this partnership is a commitment to the women driving maternal health research. Mativa will offer advanced genomic analysis as a free benefit to enrollees in the MatBank clinical study. By leveraging UGenome's expertise, Mativa is giving back to study participants, providing them clear, actionable health insights—a level of transparency and return value rarely seen in traditional trials.
Ahead of regulatory approval for its MSight Home Diagnostic Device Platform, Mativa will also offer genomic testing as a premium, fee-for-service feature on its upcoming MatHealth App. This will allow users to obtain comprehensive genomic analyses for themselves, their partner, and their children.
More on EntSun News
This dual-pronged approach drives immediate fee-for-service revenue while incentivizing clinical enrollment. By layering UGenome AI's analytics over the massive clinical data generated through MatBank, Mativa is positioned to establish MatBank as a de-risked, valuable data asset for future therapeutic and diagnostic development. Dean Remy, the Co-Founder & COO/CCO states, "Mativa is redefining the maternal health landscape, not just in technology, but in how clinical trials are conducted. Partnering with UGenome allows us to give sensitive health data back to the women helping us build MatBank. Coupling this ethical approach to trial enrollment with a direct-to-consumer, fee-for-service offering in our MatHealth app demonstrates our commitment to immediate market impact and capital-efficient growth." UGenome Founder Zachary S. Brooks shares, "UGenome is thrilled to work with Mativa Diagnostics to support women and maternal health because it has such a huge benefit on everyone connected with material health: Everyone."
More on EntSun News
About Mativa Diagnostics
Mativa Diagnostics is an ultrasensitive detection, data & biomarker IP-driven company transforming maternal health. Mativa is advancing the MSight Pregnancy and Risk Factor Home Testing Platform designed to identify critical risk factors like ectopic pregnancy and preeclampsia with unparalleled sensitivity. By integrating proprietary physical diagnostics with the MatHealth App and the MatBank biorepository, Mativa is creating a uniquely valuable, longitudinal data asset that de-risks investment while providing proactive, comprehensive care pathways for women globally. Visit us at https://www.mativadx.com
About UGenome AI
UGenome is a multiomics software and analytics company dedicated to making genomic medicine more accessible. Through their Seq4Life™ and DNA2Health™ pharmacogenomic and wellness tools respectively, UGenome empowers clinicians and individuals with proactive actionable genomic insights across wellness, women's health, medication response, and broader health domains. For more info, visit ugenome.io.
A core pillar of this partnership is a commitment to the women driving maternal health research. Mativa will offer advanced genomic analysis as a free benefit to enrollees in the MatBank clinical study. By leveraging UGenome's expertise, Mativa is giving back to study participants, providing them clear, actionable health insights—a level of transparency and return value rarely seen in traditional trials.
Ahead of regulatory approval for its MSight Home Diagnostic Device Platform, Mativa will also offer genomic testing as a premium, fee-for-service feature on its upcoming MatHealth App. This will allow users to obtain comprehensive genomic analyses for themselves, their partner, and their children.
More on EntSun News
- Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
- Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
- Contracting Resources Group Named to Inc. 5000 for the Ninth Time
- New Wave Of Independent Film: Aevolum Cinema Presents Returns With "Cornered", 30 Sept 2026
- Spooky Ventures, Tales of Wonder and Dread and Frankenstein
This dual-pronged approach drives immediate fee-for-service revenue while incentivizing clinical enrollment. By layering UGenome AI's analytics over the massive clinical data generated through MatBank, Mativa is positioned to establish MatBank as a de-risked, valuable data asset for future therapeutic and diagnostic development. Dean Remy, the Co-Founder & COO/CCO states, "Mativa is redefining the maternal health landscape, not just in technology, but in how clinical trials are conducted. Partnering with UGenome allows us to give sensitive health data back to the women helping us build MatBank. Coupling this ethical approach to trial enrollment with a direct-to-consumer, fee-for-service offering in our MatHealth app demonstrates our commitment to immediate market impact and capital-efficient growth." UGenome Founder Zachary S. Brooks shares, "UGenome is thrilled to work with Mativa Diagnostics to support women and maternal health because it has such a huge benefit on everyone connected with material health: Everyone."
More on EntSun News
- ImagineX Named to 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
- ASSIST Software Becomes One of the First European Companies Certified to ISO/IEC 42001
- The World's No.1 Superstar® Enters the Occult with New Track and Cinematic Visual "Under Your Spell"
- PricZone Launches Online Shopping Platform Offering Electronics, Gaming, and More
- In My Sundays Announces First-ever Collaboration With Realtree
About Mativa Diagnostics
Mativa Diagnostics is an ultrasensitive detection, data & biomarker IP-driven company transforming maternal health. Mativa is advancing the MSight Pregnancy and Risk Factor Home Testing Platform designed to identify critical risk factors like ectopic pregnancy and preeclampsia with unparalleled sensitivity. By integrating proprietary physical diagnostics with the MatHealth App and the MatBank biorepository, Mativa is creating a uniquely valuable, longitudinal data asset that de-risks investment while providing proactive, comprehensive care pathways for women globally. Visit us at https://www.mativadx.com
About UGenome AI
UGenome is a multiomics software and analytics company dedicated to making genomic medicine more accessible. Through their Seq4Life™ and DNA2Health™ pharmacogenomic and wellness tools respectively, UGenome empowers clinicians and individuals with proactive actionable genomic insights across wellness, women's health, medication response, and broader health domains. For more info, visit ugenome.io.
Source: Mativa Diagnostics
0 Comments
Latest on EntSun News
- Camden Contemporary Dance Theatre Turns Passion Into Purpose
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea
- Hire Movie Cars Provides Consistent Access to Camera-Ready Vehicles
- Prop Car Rental Enhances Logistics Support for Television and Film Projects
- Rebrand Complete: 58 Year Old Spicy Gamer — Blog, YouTube, and Patreon Now Aligned
- The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
- The Audience Never Left. The Connection Did
- FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
- Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
- Whitney Amor Releases Powerful New Single "Accept Me As I Am"
- Atlas Elite Entertainment Launches Monthly Press Publication Celebrating Excellence, Entertainment
- Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors
- Akiti the Hunter Series Breaks Into Amazon's Top 5 Bestsellers, Claims #1 New Release Spot
- Black Ribbon Productions Launches With Fearless 2026 Horror Slate
- Actor Dominic Pace Returns to Television and Film
- Staged Reading of "Camp Siegfried" 8/20 at St. Louis Kaplan Feldman Holocaust Museum
- Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services
- Silicon Box Ships 500M Units at High Yield, Expands Production Capacity for Panel-Level Packaging
- Dress to Kill. Aim for Greatness